Nuvectis Pharma, Inc.
Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
About
CEO
Mr. Ron Bentsur M.B.A.
Employees
13
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
1 Bridge Plaza, Fort Lee, NJ 07024, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 8, 2023 | -0.34 | -0.37 | -0.03 | 8.82% |
| Aug 9, 2023 | -0.29 | -0.38 | -0.09 | 31.03% |
| May 10, 2023 | -0.44 | -0.27 | 0.17 | -38.64% |
| Mar 7, 2023 | -0.38 | -0.48 | -0.10 | 26.32% |
| Nov 8, 2022 | -0.27 | -0.42 | -0.15 | 55.56% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 0 | — | 0 |
| Average estimate | — | 0.00 | — | 0.00 |
| Low estimate | — | 0.00 | — | 0.00 |
| High estimate | — | 0.00 | — | 0.00 |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year
—
Next year (Dec 2025)
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total reported revenue | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Operating expense | |||
| Research & development | 15.38M | 13.23M | 9.55M |
| Selling general and admin | 7.52M | 6.01M | 3.35M |
| Other operating expenses | — | — | — |
| Operating income | -22.90M | -19.23M | -12.89M |
| Non operating interest income | |||
| Income | 637,000 | 149,000 | 4,000 |
| Expense | — | — | — |
| Other income expense | — | — | — |
| Pretax income | -22.26M | -19.09M | -12.89M |
| Tax provision | — | — | — |
| Net income | -22.26M | -19.09M | -12.89M |
| Basic EPS | -1.43 | -1.51 | -1.09 |
| Diluted EPS | -1.43 | -1.51 | -1.09 |
| Basic average shares | 15.56M | 12.66M | 12.72M |
| Diluted average shares | 15.56M | 12.66M | 12.72M |
| EBITDA | -22.90M | -19.23M | -12.89M |
| Net income from continuing op. | -22.26M | -19.09M | -12.89M |
| Minority interests | — | — | — |
| Preferred stock dividends | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 19.19M | 20.41M | 6.66M | — |
| Current assets | ||||
| Cash | — | — | — | — |
| Cash equivalents | — | — | — | — |
| Cash and cash equivalents | 19.13M | 19.99M | 5.74M | — |
| Other short term investments | — | — | — | — |
| Accounts receivable | — | — | — | — |
| Other receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Prepaid assets | — | — | — | — |
| Restricted cash | — | — | — | — |
| Assets held for sale | — | — | — | — |
| Hedging assets | — | — | — | — |
| Other current assets | 59,000 | 412,000 | 91,000 | — |
| Non current assets | ||||
| Properties | — | — | — | — |
| Land and improvements | — | — | — | — |
| Machinery furniture equipment | — | — | — | — |
| Construction in progress | — | — | — | — |
| Leases | — | — | — | — |
| Accumulated depreciation | — | — | — | — |
| Goodwill | — | — | — | — |
| Investment properties | — | — | — | — |
| Financial assets | — | — | — | — |
| Intangible assets | — | — | — | — |
| Investments and advances | — | — | — | — |
| Other non current assets | — | — | 824,000 | — |
| Total liabilities | 6.98M | 6.19M | 17.67M | 10,000 |
| Current liabilities | ||||
| Accounts payable | 2.77M | 2.91M | 1.06M | 10,000 |
| Accrued expenses | 415,000 | 445,000 | 395,000 | — |
| Short term debt | — | — | — | — |
| Deferred revenue | — | — | — | — |
| Tax payable | — | — | — | — |
| Pensions | 3.80M | 2.38M | 142,000 | — |
| Other current liabilities | — | — | — | — |
| Non current liabilities | ||||
| Long term debt | — | — | — | — |
| Provision for risks and charges | — | — | — | — |
| Deferred liabilities | — | — | — | — |
| Derivative product liabilities | — | — | — | — |
| Other non current liabilities | — | — | — | — |
| Shareholders equity | ||||
| Common stock | — | — | — | — |
| Retained earnings | -54.25M | -31.99M | -12.90M | -10,000 |
| Other shareholders equity | — | — | — | — |
| Total shareholders equity | 12.20M | 14.22M | -11.01M | -10,000 |
| Additional paid in capital | 66.45M | 46.20M | 1.89M | — |
| Treasury stock | — | — | — | — |
| Minority interest | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -22.26M | -19.09M | -12.89M |
| Depreciation | — | — | — |
| Deferred Taxes | — | — | — |
| Stock-Based Compensation | 4.71M | 1.71M | 1.89M |
| Other Non-Cash Items | — | — | — |
| Accounts Receivable | — | — | — |
| Accounts Payable | -139,000 | 1.85M | — |
| Other Assets & Liabilities | 1.77M | 1.63M | -91,000 |
| Operating Cash Flow | -15.92M | -13.90M | -11.09M |
| Investing Activities | |||
| Capital Expenditures | — | — | — |
| Net Intangibles | — | — | — |
| Net Acquisitions | — | — | — |
| Purchase of Investments | — | — | — |
| Sale of Investments | — | — | — |
| Investing Cash Flow | — | — | — |
| Financing Activities | |||
| Long-Term Debt Issuance | — | — | — |
| Long-Term Debt Payments | — | — | — |
| Other Financing Charges | -1.39M | -4.07M | — |
| Financing Cash Flow | 3.90M | 27.81M | 15.25M |
| Other Cash Details | |||
| End Cash Position | 19.13M | 19.99M | 5.74M |
| Income Tax Paid | — | — | — |
| Interest Paid | — | — | — |
| Free Cash Flow | -15.95M | -13.56M | -9.50M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 231,040 | 1.67M | 1.20% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 57,030 | 412,897 | 0.30% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 37,202 | 269,342 | 0.19% |
| iShares Micro Cap ETF | Nov 30, 2024 | 21,218 | 153,618 | 0.11% |
| Fidelity Total Market Index Fund | Nov 30, 2024 | 13,310 | 96,364 | 0.07% |
| Fidelity Series Total Market Index Fund | Nov 30, 2024 | 8,883 | 64,312 | 0.05% |
| Fidelity NASDAQ Composite Index Fund | Nov 30, 2024 | 10,226 | 74,036 | 0.05% |
| Vanguard Balanced Index Fund | Sep 30, 2024 | 5,600 | 40,543 | 0.03% |
| Vanguard Institutional Index-Inst Total Stock Market Ind | Sep 30, 2024 | 5,612 | 40,630 | 0.03% |
| Schwab Capital Trust-Total Stock Market Index Fund | Oct 31, 2024 | 2,330 | 16,869 | 0.01% |
Article
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option
FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock, and the exercise in full of the underwriter's option to purchase 405,000 additional shares. The common stock shares were offered at a price of $5.00 per share, resulting in gross proceeds to Nuvectis of approximately $15.5 million, before deducting underwriting discounts and commissions.
Feb 7, 2025
Article
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback
The company's stock dropped due to disappointing phase 1b results for NXP800 in ARID1a-mutated ovarian cancer, but higher dosing may improve outcomes in Q2 2025. The company is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting toxicities. The global ovarian cancer market is expected to reach $11.18 billion by 2029.
Feb 6, 2025
Article
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price of $5.00 per share, with expected gross proceeds to Nuvectis of $13.5 million. Nuvectis has also granted the underwriter a 30-day option to purchase up to 405,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 6, 2025, subject to customary closing conditions.
Feb 5, 2025
